Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Continues Reviewing Marketing Reports, Will It Punish Scofflaws?

Aug 19 2018

• By Derrick Gingery

FDAEntrance_1200x675

Related Content

FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

Aug 05 2017

US FDA's Generic Research May Include EpiPen And Competitors

Apr 10 2018

Outlook For Orange Book Update Not Too Rosy

Apr 19 2018

Teva To Launch First Generic EpiPen In 'Coming Months'; FDA Heralds Approval Of Complex Product

Aug 16 2018

Inside The ANDA Parking Lot

Jun 14 2018

US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs

Jun 07 2018

Drug Sponsors Who Fail To Submit One-Time Marketing Report Face Big Penalty

Feb 08 2018

Related Companies

Teva Pharmaceutical Industries Ltd.

Viatris Inc.

Sanofi

Novartis AG

Additional Topics

United States Generic Drugs FDA Regulation BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window